Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Ca… (NCT00008164) | Clinical Trial Compass
UnknownPhase 2
Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia
United States30 participantsStarted 1997-01
Plain-language summary
RATIONALE: Umbilical cord blood or placental blood transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells.
PURPOSE: Phase II trial to study the effectiveness of umbilical cord blood and placental blood transplantation in treating patients who have hematologic cancer or aplastic anemia.
Who can participate
Age range60 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
DISEASE CHARACTERISTICS:
* Diagnosis of chronic myeloid leukemia, acute leukemia, lymphoma, myeloma, myelodysplasia, aplastic anemia, Fanconi's anemia, histiocytosis, hereditary immunodeficiency, or storage disorder
* Eligible for allogeneic bone marrow transplantation, but lacking a donor
* Available donor umbilical cord blood that is mismatched on no more than 2 HLA loci
* HIV negative
* Hepatitis B surface antigen and hepatitis C negative
PATIENT CHARACTERISTICS:
Age:
* Under physiologic 60
Performance status:
* Not specified
Life expectancy:
* Not specified
Hematopoietic:
* Not specified
Hepatic:
* Bilirubin less than 2 times normal
* No severe hepatic disease
* Hepatitis B surface antigen and hepatitis C negative
Renal:
* Creatinine less than 2 times normal
Other:
* HIV negative
* Not pregnant or nursing
* No other serious medical or psychiatric illness that would preclude study compliance
* No serious infection
PRIOR CONCURRENT THERAPY:
Biologic therapy
* Not specified
Chemotherapy
* Not specified
Endocrine therapy
* Not specified
Radiotherapy
* Not specified
Surgery
* Not specified